Last updated: February 23, 2026
What is NDC 70677-1005?
NDC 70677-1005 refers to Lutathera (lutetium Lu 177 dotatate), a peptide receptor radionuclide therapy (PRRT) indicated for treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). It was approved by the FDA in January 2018[1].
Market Overview
Current Market Size
The global neuroendocrine tumor therapeutics market reached approximately $1.2 billion in 2022. Lutathera accounts for a significant proportion, given its novel mechanism and targeted therapy status[2].
Competitive Landscape
- Lutathera (Synthesized by Advanced Accelerator Applications, a Novartis company) is the first approved PRRT for GEP-NETs.
- Competing therapies include everolimus (Afinitor), an mTOR inhibitor, and sunitinib (Sutent), a tyrosine kinase inhibitor.
- No direct multiplexed radiolabeled competitors are approved in this indication yet; however, research on other targeted radiotherapies persists.
Patient Population
Estimates indicate around 200,000 patients globally with GEP-NETs, with approximately 50% exhibiting somatostatin receptor positivity—a target for Lutathera[3].
Pricing and Reimbursement Dynamics
Current Price Point
- The wholesale acquisition cost (WAC) for Lutathera in the U.S. is approximately $27,500 per dose.
- Patients typically receive four doses over a 6-month cycle, leading to a total treatment cost of about $110,000 per course[4].
Reimbursement Policies
- Medicare, Medicaid, and commercial insurers generally reimburse for Lutathera at or near the WAC.
- Coverage policies consider treatment efficacy and prior therapy lines.
Market Growth Projections
Key Drivers
- Increasing diagnosis rates of neuroendocrine tumors.
- Expanded indications including potential use in other receptor-positive tumors.
- Physician comfort and familiarity with radiolabeled therapies.
Projected Market Expansion
| Year |
Estimated Market Size (USD Billion) |
Comments |
| 2023 |
1.25 |
Continued adoption and reimbursement coverage |
| 2025 |
1.75 |
Expansion into broader patient populations |
| 2030 |
2.4 |
Increased awareness and new therapeutic indications |
Sources predict a compound annual growth rate (CAGR) of approximately 12-15% between 2023 and 2030[2].
Price Projections
Short-term (Next 2 Years)
- Price remains stable at approximately $27,500 per dose.
- Slight variations may occur due to inflation and reimbursement negotiations.
Mid-term (2024-2026)
- Premium pricing could increase if clinical data demonstrates superior outcomes or if new formulations extend durability.
- Potential introduction of biosimilar or generic versions unlikely within this time frame due to complex manufacturing.
Long-term (Post-2026)
- The price could decline if a competitive radiopharmaceutical becomes FDA-approved.
- Introduction of combination therapies might influence cost dynamics.
Factors Affecting Future Pricing
- Regulatory decisions expanding indications.
- Cost-effectiveness outcomes influencing payer coverage.
- Advances in radiochemistry reducing manufacturing costs.
Risks and Opportunities
Risks
- Patent restrictions limit biosimilar entry until at least 2030.
- Reimbursement policies may tighten if cost-effectiveness is questioned.
- Competition from emerging radiolabeled therapies or alternative treatment modalities.
Opportunities
- Indication expansion into other neuroendocrine or receptor-positive tumors.
- Development of more efficient manufacturing processes to lower production costs.
- Adoption in earlier lines of therapy, increasing patient population.
Key Takeaways
- NDC 70677-1005 (Lutathera) is a leading targeted radiotherapy for neuroendocrine tumors, with a current price of around $27,500 per dose.
- The global market for neuroendocrine therapies is projected to grow at a CAGR of 12-15%, driven by increased diagnosis and expanded indications.
- Price stability is expected in the near term, with potential increases contingent on clinical and regulatory developments.
- Long-term pricing could decline if biosimilar competitors emerge or new therapies prove cost-effective.
- Revenue growth will depend on patient access, reimbursement policies, and therapeutic pipeline advances.
FAQs
-
How is Lutathera different from other neuroendocrine tumor treatments?
Lutathera delivers targeted radionuclide therapy directly to somatostatin receptor-positive tumors, offering a mechanism distinct from systemic mTOR inhibitors or kinase inhibitors.
-
What factors could cause Lutathera prices to rise?
Clinical data showing improved survival benefits, indication expansion, or increased manufacturing costs could push prices higher.
-
Is there potential for biosimilar competition?
Biosimilar versions are unlikely before 2030 due to complex manufacturing quality controls and patent protections.
-
How does reimbursement impact Lutathera’s market penetration?
Coverage is generally favorable, but cost-effectiveness analyses influence payer decisions, affecting patient access.
-
What is the outlook for Lutathera’s market in the next decade?
Market expansion will be supported by rising diagnosis rates and broader therapeutic indications, with prices remaining relatively stable short term.
References
[1] U.S. Food and Drug Administration. (2018). FDA Approves Lutathera for Gastroenteropancreatic Neuroendocrine Tumors. FDA News Release. Retrieved from https://www.fda.gov
[2] MarketsandMarkets. (2022). Neuroendocrine Tumors Market by Type, Treatment, and Region. Report ID: 4678.
[3] Chen, H., et al. (2020). Epidemiology and Treatment Trends for Gastroenteropancreatic Neuroendocrine Tumors. Cancer Epidemiology, 66, 101793.
[4] IQVIA. (2022). National Prescription Data.
